SC
Sangel Capital
Venture CapitalActiveSangel Capital is a biomedical venture capital firm
15
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Sangel Capital.
Investment Thesis & Strategy
Sangel Capital invests in various stages of biomedical companies. They focus on companies within the biomedical sector.
Investment Activity
Deals per year over the last 5 years
1
20142
20152
20163
20173
2018Portfolio Companies
Selected investments from their portfolio of 15 companies
T
Triumvira Immunologics
Biotech · Series A, 2018
A
Aura Biosciences
Biotech · Series A, 2018
V
Vaxcyte
Biotech · Series A, 2018
O
Obsidian Therapeutics
Biotech · Series A, 2017
P
Pliant Therapeutics
Biotech · Series A, 2017
C
Cabaletta Bio
Biotech · Series A, 2017
S
Surface Oncology
Biotech · Series A, 2016
N
NextCure
Biotech · Series A, 2016
R
Revolution Medicines
Biotech · Series A, 2015
I
Immatics
Biotech · Series C+, 2015
K
Kura Oncology
Biotech · Series A, 2014
Frequently Asked Questions
Sangel Capital focuses on Series A, Series B, Series C+ stage investments.